The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.

The company's immunotherapy failed to improve survival of pancreatic patients compared to chemotherapy. Lilly will be hoping pegilodecakin has more success in NSCLC.

Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be driven in the third quarter by its portfolio of new medicines. It still believes its delayed takeover of Spark Therapeutics will happen by year-end.  

The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.

The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.

While industry participants at BioJapan expect big pharma to continue to seek external partnerships and acquisitions to bolster pipelines, the technology and countries involved in such alliances look set to change.

With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options for patients with the rare bone disease.

Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.

In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around 30 selected OTC and Rx products in certain Middle East and other emerging markets to private Swiss group Acino.

Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.

Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug it out in court over alleged patent infringement charges.

Indian firm Granules is exiting its long-standing joint venture for ibuprofen API in China against the backdrop of evolving pollution control norms and the need for growing expenditure there, while emerging supply options have reduced the need for a local JV.

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.  

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Denmark has generated high growth rates from its life science industry. The country's government, industry and academic centers are increasingly working together to keep up that momentum.

The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?

Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.